1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy. - Starodub, A.N.; Kim, S-B.; Davar, D.; Powderly, J.; Hill, A.G.; Yeku, O.; Gabrail, N.; Krapp, C.; Pihl, S.; Chen, M.; Slavsky, S.; Torrejon Castro, D.; et al. (Annals of Oncology, 2023)